Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Condition(s):Von Willebrand Disease, Type 3; Concomitant VWD and HemophiliaLast Updated:March 1, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Von Willebrand Disease, Type 3; Concomitant VWD and HemophiliaLast Updated:March 1, 2023Recruiting
Condition(s):Hemophilia ALast Updated:February 9, 2024Not yet recruiting
Condition(s):Severe Hemophilia A Without Inhibitor; Joint BleedLast Updated:March 5, 2024Recruiting
Condition(s):Acquired Hemophilia ALast Updated:February 26, 2024Recruiting
Condition(s):Hemophilia ALast Updated:October 30, 2023Not yet recruiting
Condition(s):Hemophilia ALast Updated:August 1, 2023Recruiting
Condition(s):Hemophilia ALast Updated:February 6, 2024Recruiting
Condition(s):Hemophilia A With Inhibitor; Hemophilia A Without Inhibitor; Hemophilia A, Severe; Adolescent; Child; AdultLast Updated:March 20, 2024Recruiting
Condition(s):Hemophilia ALast Updated:December 22, 2023Recruiting
Condition(s):Hemophilia ALast Updated:February 10, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.